Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jubilant Organosys Of India Seeks CRO-Related Acquisitions In U.S., Europe (India)

This article was originally published in PharmAsia News

Executive Summary

India's Jubilant Organosys has set aside $100 million to acquire companies in the clinical research area in the United States and Europe. Specifically, Jubilant wants companies engaging in contract research and manufacturing services, drug discovery and clinical research. The company seeks to position itself as a source for outsourcing partnerships with major global drug makers and as a service provider, according to the firm's finance director. Jubilant already has contract research-organization subsidiaries in the United States and India. (Click here for more

You may also be interested in...



Amarin's Vascepa May Face Generic Competition In US Next Year After Patents Ruled Invalid

Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.

Covid-19 Scam Complaints Double In A Week, But FTC Enforcement Considers 'Good Faith' Factor

FTC pursuing bogus health and other products or services capitalizing on Covid-19 fear with scams skyrocketing. However, FTC says its enforcement will consider whether businesses are making good faith efforts to produce products in high demand.

No Facility Inspections? No Shortage Of Bogus Pandemic Claims Found Online By US Agencies

Warning letters show FDA's coronavirus investigations inthe consumer health marketplace didn't stop when it suspended facility inspections. The letters identify firms that previously marketed only bedding products as offering supplements with coronavirus claims or that are in other countries and are shipping to US consumers products promoted with coronavirus claims.

UsernamePublicRestriction

Register

SC065960

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel